|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
6
|
|
gptkbp:bfsParent
|
gptkb:fluorouracil
|
|
gptkbp:activities
|
gptkb:fragrance
|
|
gptkbp:affects
|
DNA synthesis
RNA synthesis
|
|
gptkbp:appointed_by
|
injection
|
|
gptkbp:approves
|
gptkb:1962
gptkb:FDA
|
|
gptkbp:brand
|
gptkb:fluorouracil
|
|
gptkbp:can_be_used_with
|
other chemotherapy drugs
|
|
gptkbp:clinical_trial
|
gptkb:healthcare_organization
ongoing
stomach cancer
head and neck cancer
|
|
gptkbp:contraindication
|
pregnancy
breastfeeding
severe liver disease
|
|
gptkbp:discovered_by
|
1950s
|
|
gptkbp:dosage_form
|
500 mg/m2
|
|
gptkbp:excretion
|
urine
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Adrucil
|
|
gptkbp:ingredients
|
gptkb:fluorouracil
C4 H3 F N2 O2
|
|
gptkbp:interacts_with
|
gptkb:methotrexate
gptkb:cisplatin
gptkb:warfarin
|
|
gptkbp:invention
|
patented
|
|
gptkbp:is_available_on
|
generic drug
|
|
gptkbp:is_monitored_by
|
blood tests
|
|
gptkbp:is_used_for
|
treating cancer
|
|
gptkbp:lifespan
|
8 to 20 minutes
|
|
gptkbp:manager
|
intravenous
|
|
gptkbp:marketed_as
|
multiple countries
various pharmaceutical companies
|
|
gptkbp:packaging
|
vials
|
|
gptkbp:pharmacokinetics
|
metabolized in liver
|
|
gptkbp:requires
|
gptkb:theorem
|
|
gptkbp:research_focus
|
patient quality of life
dosage optimization
combination therapies
resistance mechanisms
new formulations
|
|
gptkbp:side_effect
|
nausea
allergic reactions
vomiting
diarrhea
neurotoxicity
cardiotoxicity
pulmonary toxicity
mouth sores
low blood cell counts
|
|
gptkbp:storage
|
room temperature
|
|
gptkbp:suitable_for
|
gptkb:Person
elderly patients
|
|
gptkbp:treatment
|
28 days
|
|
gptkbp:weight
|
130.08 g/mol
|